Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPX NASDAQ:ERAS NASDAQ:SAVA NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$3.15+0.6%$2.41$0.87▼$4.08$432.82M1.48986,706 shs1.24 million shsERASErasca$1.49+3.5%$1.39$1.01▼$3.45$407.93M1.051.59 million shs915,350 shsSAVACassava Sciences$2.10+1.4%$2.04$1.15▼$42.20$100M-2.042.80 million shs666,120 shsSNDLSNDL$1.56+4.7%$1.31$1.15▼$2.40$391.54M3.41.96 million shs1.91 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics+5.03%+14.23%+32.07%+78.86%+198.10%ERASErasca+2.13%-6.49%+2.49%+24.14%-55.42%SAVACassava Sciences+0.49%-5.48%+0.98%+43.75%-84.70%SNDLSNDL-1.32%+4.93%+12.03%+6.43%-32.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPXCompass Therapeutics3.0647 of 5 stars3.61.00.00.03.45.00.0ERASErasca2.9485 of 5 stars3.52.00.00.02.22.51.3SAVACassava Sciences4.1614 of 5 stars3.33.00.04.72.70.01.3SNDLSNDL1.5493 of 5 stars2.03.00.00.01.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPXCompass Therapeutics 3.10Buy$12.67302.12% UpsideERASErasca 3.00Buy$4.57206.81% UpsideSAVACassava Sciences 2.50Moderate Buy$54.502,495.24% UpsideSNDLSNDL 0.00N/A$4.00156.41% UpsideCurrent Analyst Ratings BreakdownLatest SAVA, SNDL, ERAS, and CMPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025CMPXCompass TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform$9.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/22/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/21/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPXCompass Therapeutics$850K512.45N/AN/A$0.91 per share3.46ERASErascaN/AN/AN/AN/A$1.50 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ASNDLSNDL$671.81M0.61N/AN/A$3.15 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPXCompass Therapeutics-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)ERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)SAVACassava Sciences-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/14/2025 (Estimated)SNDLSNDL-$69.18M-$0.29N/AN/AN/A-11.48%-9.02%-7.60%7/30/2025 (Estimated)Latest SAVA, SNDL, ERAS, and CMPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13N/AN/AN/AN/AN/A8/11/2025Q2 2025ERASErasca-$0.12N/AN/AN/AN/AN/A8/7/2025Q2 2025SNDLSNDL-$0.04N/AN/AN/A$231.50 millionN/A5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/A5/1/2025Q1 2025SNDLSNDL-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPXCompass TherapeuticsN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPXCompass TherapeuticsN/A8.338.33ERASErascaN/A12.3512.35SAVACassava SciencesN/A9.089.08SNDLSNDL0.104.623.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPXCompass Therapeutics68.43%ERASErasca67.78%SAVACassava Sciences38.05%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipCMPXCompass Therapeutics29.80%ERASErasca14.40%SAVACassava Sciences2.40%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableERASErasca120283.29 million242.49 millionOptionableSAVACassava Sciences3048.31 million47.15 millionOptionableSNDLSNDL2,516262.78 millionN/AOptionableSAVA, SNDL, ERAS, and CMPX HeadlinesRecent News About These CompaniesSNDL to Announce Second Quarter 2025 Financial Results on ... - MorningstarJuly 12, 2025 | morningstar.comMSNDL Inc. to Release Q2 2025 Financial Results on July 31July 10, 2025 | tipranks.comSNDL to Announce Second Quarter 2025 Financial Results on July 31, 2025July 10, 2025 | prnewswire.comSundial Raises $23M to Redefine Data-informed Decisions with AIJuly 8, 2025 | businesswire.com3 Marijuana Stocks For The Investor To Consider Before A RecoveryJuly 7, 2025 | marijuanastocks.comMSNDL (NASDAQ:SNDL) Trading 2% Higher - Here's What HappenedJuly 4, 2025 | marketbeat.comSNDL Inc. Announces Virtual Annual and Special Shareholders Meeting for July 2025June 20, 2025 | tipranks.com3 Cannabis Stocks For Investors To Secure For Future GainsJune 20, 2025 | marijuanastocks.comM1CM Receives Court Approval for Arrangement with SNDL IncJune 18, 2025 | newsfilecorp.comN1CM Inc. Gains Court Approval for SNDL ArrangementJune 18, 2025 | tipranks.comHYTN Receives Initial International Purchase Order for GMP Vape CartridgesJune 11, 2025 | finance.yahoo.comMarijuana Stocks To Watch With Strong Market PotentialJune 6, 2025 | marijuanastocks.comM1CM Mails Circular for Annual and Special Meeting of Shareholders and Announces Receipt of Interim Court OrderMay 20, 2025 | finance.yahoo.comCanadian Securities Exchange Reports April 2025 Performance FiguresMay 15, 2025 | finance.yahoo.comSA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLIMay 5, 2025 | msn.comSNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has IncreasedMay 5, 2025 | seekingalpha.comSNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call TranscriptMay 3, 2025 | insidermonkey.comSNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2025 | finance.yahoo.com3 Marijuana Stocks For The Long Term InvestingMay 2, 2025 | marijuanastocks.comMSNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market ReviewMay 2, 2025 | uk.finance.yahoo.comThese Cannabis Companies Are Repurchasing SharesMay 2, 2025 | newcannabisventures.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAVA, SNDL, ERAS, and CMPX Company DescriptionsCompass Therapeutics NASDAQ:CMPX$3.15 +0.02 (+0.64%) Closing price 04:00 PM EasternExtended Trading$3.20 +0.05 (+1.59%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Erasca NASDAQ:ERAS$1.49 +0.05 (+3.47%) Closing price 04:00 PM EasternExtended Trading$1.48 -0.01 (-0.67%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Cassava Sciences NASDAQ:SAVA$2.10 +0.03 (+1.45%) Closing price 04:00 PM EasternExtended Trading$2.10 0.00 (-0.24%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.SNDL NASDAQ:SNDL$1.56 +0.07 (+4.70%) Closing price 04:00 PM EasternExtended Trading$1.56 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
